



ADHD medicines

CORE TAKEAWAY

~\$14–22B global. Evidence gap: no dedicated microgravity campaigns found on core stimulants/non-stimulants. Fit is formulation and process, not clinical efficacy in orbit.

FRANKLIN 1 FIT

- ADHD medicines are a large commercial class with almost no published microgravity formulation work.
- Franklin 1 maps crystallization and solid-state windows (thermal, mixing, concentration) and downlinks prioritized packets.
- This brief is process/formulation only. No organoid, culture, or regenerative claims for this iteration.
- Pathfinder targeted 2027, partner- and funding-gated.
- Not a claim that Franklin treats ADHD.

Franklin 1 is a data-first microgravity process payload. It complements return platforms and ISS slots; it does not replace them. Atom One Space does not claim to treat or cure any disease in orbit.